Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Trader J who wrote (2932)	1/1/1999 11:08:00 AM
From: Len	Respond to of 56535

To All: Here is my first suggestion on this thread--well, maybe my second. CEPH: Cephalon is a biotech that just got approval for Provigil, a drug initially designed to treat narcolepsy. Some believe the real potential is in other "Off Label" uses. Upon approval the stock ticked up and then gave back all the gains. Yeterday, it rebounded and was up 1 1/8 to $9. Michael Murphy is predicting $1.00 earnings in 2000. The stock has not done real well. The reason I am suggesting it be looked at is that the company will hold a conference call on Tuesday and will present at the H&Q conference on Jan 12 or 13. It is possible that this attention will get the stock to move. Just my thoughts. Good luck Len

To: Trader J who wrote (2932)	1/1/1999 11:55:00 AM
From: Trader J	Read Replies (1) \| Respond to of 56535

ASCT: Have been told that management has been in meetings this entire week but there is no confirmation on what they are about. Be prepared for some volatility here as traders are starting to see the value in ASCT as a trading vehicle. A 3 1/2 dollar stock that can swing 1 1/4 intraday is a valuable commodity....while it lasts. I expect to see continued good volume over the next week. I doubt that I will trade it as I probably should....I will not miss the announcement if/when it happens. TJ